Pay in 4 interest-free payments of $7.39 Learn more
Ships within 48 hours · Estimated delivery Aug 28 - Sep 2
Clinical Background BPC-157 was introduced in 1993 and initially studied as a potential treatment for inflammatory bowel disease due to its anti-ulcer effects
Those with absorption difficulties, such as pernicious anaemia or following gastric surgery, may require significantly higher doses or intramuscular injections as prescribed by their healthcare provider
Instead, it acts as a stabilizer, keeping dopamine and serotonin levels balanced within a normal range
( Lancet 2023, NCT04982575 [12] ) randomised 92 adults with type 2 diabetes on metformin, with or without an SGLT2 inhibitor, 1:1:1 to CagriSema (n=31), semaglutide (n=31), or cagrilintide (n=30), all escalated to 2.4 mg, across 17 US sites over 32 weeks
US$ 21.68
US$ 29.06
US$ 28.46
